BBI

Brickell Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9319
-0.0161
-1.70%
After Hours: 0.9300 -0.0019 -0.20% 17:57 07/10 EDT
OPEN
0.9480
PREV CLOSE
0.9480
HIGH
0.9480
LOW
0.9110
VOLUME
637.68K
TURNOVER
--
52 WEEK HIGH
6.51
52 WEEK LOW
0.8816
MARKET CAP
22.80M
P/E (TTM)
-0.0741
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BBI stock price target is 1.800 with a high estimate of 1.800 and a low estimate of 1.800.

EPS

BBI News

More
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 1d ago
INO, PEI among premarket gainers
Seeking Alpha - Article · 06/23 12:27
NES, ISEE, QUIK and BBI among midday movers
Seeking Alpha - Article · 06/18 16:44
SSL, CCL among premarket losers
Seeking Alpha - Article · 06/18 12:51
Brickell Biotech Shares Down ~17% Premarket Following Late Wed. Pricing Of 17.5M Share Offering At $1.15/Share
Benzinga · 06/18 11:23
Brickell Bio drops 15% after pricing $20.1M equity offering
Seeking Alpha - Article · 06/18 08:38
Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering
GlobeNewswire · 06/18 03:00
CLIR, IDEX, ENPH and BBI among midday movers
Seeking Alpha - Article · 06/17 16:41

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About BBI

Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.
More

Webull offers kinds of Brickell Biotech Inc stock information, including NASDAQ:BBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BBI stock methods without spending real money on the virtual paper trading platform.